摘要
目的探讨瑞舒伐他汀对扩张型心肌病患者血清基质金属蛋白酶-9(MMP-9)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)和高敏C-反应蛋白(hs-CRP)的影响。方法将76例扩张型心肌病患者随机分为瑞舒伐他汀组和对照组(常规治疗组),各38例。瑞舒伐他汀组在常规治疗基础上给予瑞舒伐他汀片10 mg,每天服用1次,治疗8周。测定治疗前后血清MMP-9、IL-6、TNF-α和hs-CRP水平,并进行比较。结果治疗前两组患者血清MMP-9、IL-6、TNF-α和hs-CRP水平比较,差异无统计学意义(P>0.05),治疗后瑞舒伐他汀组患者血清MMP-9、IL-6、TNF-α和hs-CRP水平较对照组明显降低,差异有统计学意义(P<0.05)。结论扩张型心肌病的发生与机体炎性反应激活有关,瑞舒伐他汀能够降低扩张型心肌病患者血清MMP-9、IL-6、TNF-α和hs-CRP水平,尤其在并发心功能不全的治疗中具有重要作用。
Objective To investigate the influence of rosuvastatin on serum matrix metalloproteinase-9（MMP-9）,interleukin-6（IL-6）,tumor necrosis factor alpha（TNF-α） and high-sensitivity C-reactive protein（hs-CRP） in the patients with dilated cardiomyopathy（DCM）.Methods 76 patients with DCM were randomly divided into the rosuvastatin group and the routine treatment group（control group） equally.The rosuvastatin group was added with rosuvastatin tablet 10 mg,once daily for 8 weeks on the basis of the conventional therapy.Serum MMP-9,IL-6,TNF-α and hs-CRP levels before and after treatment were tested and compared.Results The serum MMP-9,IL-6,TNF-α and hs-CRP levels before treatment had no statistical difference between the two groups（P0.05）;the serum MMP-9,IL-6,TNF-α and hs-CRP levels after treatment in the rosuvastatin group were decreased more obviously than those in the control group,the difference was statistically significant（P0.05）.Conclusion The occurrence of DCM is related with the activation of the body inflammatory reaction.Rosuvastatin can reduce serum MMP-9,IL-6,TNF-α and hs-CRP levels in DCM patients and has the important role especially in treating complicating cardiac insufficiency.
出处
《现代医药卫生》
2013年第14期2087-2089,共3页
Journal of Modern Medicine & Health
